CHRO — ChromoGenics AB Income Statement
0.000.00%
Last trade - 00:00
- SEK26.81m
- SEK85.71m
- SEK13.65m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 45.2 | 14.6 | 24.7 | 18.3 | 13.6 |
Cost of Revenue | |||||
Gross Profit | -3.22 | 0.141 | 8.75 | 3.3 | 7.08 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 120 | 71.4 | 84.3 | 74.2 | 62.4 |
Operating Profit | -74.9 | -56.8 | -59.7 | -55.9 | -48.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -77.9 | -62.5 | -63.5 | -57 | -52.5 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -99,334 | -18,994 | -27,120 | -2,896 | -19.8 |
Dividends per Share |